CymaBay Therapeutics Inc (CBAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
56
About the Report
About the Report
Summary
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company's pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.
CymaBay Therapeutics Inc (CBAY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
CymaBay Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
Partnerships 12
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
Equity Offering 13
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23
CymaBay Therapeutics Inc-Key Competitors 24
CymaBay Therapeutics Inc-Key Employees 25
CymaBay Therapeutics Inc-Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Nov 06, 2018: CymaBay reports third quarter 2018 financial results and provides corporate update 27
Nov 06, 2018: Cymabay reports third quarter 2018 financial results and provides corporate update 29
Aug 09, 2018: Cymabay reports second quarter 2018 financial results and provides corporate update 31
May 08, 2018: CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 15, 2018: CymaBay Announces Fourth Quarter and Fiscal 2017 Financial Results 34
Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates 36
Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results 40
Corporate Communications 41
Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. 41
Product News 42
10/31/2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer 42
06/19/2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 43
01/08/2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis 44
01/08/2018: CymaBay Therapeutics Receives USD 5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America 45
Product Approvals 46
Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis 46
Clinical Trials 47
May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis 47
Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 48
Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis 50
Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting 51
Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology 52
Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis 53
Apr 13, 2017: CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 54
Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Figure
List of Figures
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For USD 33.2 Million 23
CymaBay Therapeutics Inc, Key Competitors 24
CymaBay Therapeutics Inc, Key Employees 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.